By Rob Wright, Chief Editor, Life Science Leader
Follow Me On Twitter @RfwrightLSL
IN 2018, Norbert Bischofberger, Ph.D., received an odd text from biopharma serial entrepreneur Arie Belldegrun, M.D.
The two men had met the year prior when Belldegrun’s company, Kite Pharma, was in the throes of being acquired by Gilead Sciences, where Bischofberger had worked since 1990. The text simply said, “You have to meet Chris W.”
Not only did Bischofberger not know who Chris W. was, he didn’t know why he should meet with him. He also didn’t know that this one text would ultimately change the course of his career.